Budget Amount *help |
¥26,650,000 (Direct Cost: ¥20,500,000、Indirect Cost: ¥6,150,000)
Fiscal Year 2010: ¥12,610,000 (Direct Cost: ¥9,700,000、Indirect Cost: ¥2,910,000)
Fiscal Year 2009: ¥14,040,000 (Direct Cost: ¥10,800,000、Indirect Cost: ¥3,240,000)
|
Research Abstract |
The purpose of this study was to explore a novel adjuvant aimed at re-activation of macrophage cells, which may improve the therapeutic efficacy of cancer vaccines. We conducted clinical trial of WT1 peptide vaccine with CpG or GM-CSF combination therapy, and examined its safety and efficacy. As a result, GM-CSF and CpG was found to be safely combined immunopotentiating adjuvants.
|